{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:52:33Z","timestamp":1771210353882,"version":"3.50.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,30]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Endogenous CyPG PGJ2 targets LSCs through PPAR\u03b3 activation. Selenium supplementation could serve as an adjunct therapy for CML.<\/jats:p>","DOI":"10.1182\/blood-2016-08-736405","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T02:55:15Z","timestamp":1485226515000},"page":"1802-1810","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Activation of PPAR\u03b3 by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia"],"prefix":"10.1182","volume":"129","author":[{"given":"Emily R.","family":"Finch","sequence":"first","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"},{"name":"Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diwakar B.","family":"Tukaramrao","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"},{"name":"Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Goodfield","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Quickel","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Paulson","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Sandeep","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Department of Veterinary and Biomedical Sciences,"},{"name":"Center for Molecular Immunology and Infectious Diseases, and"},{"name":"Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"14","key":"2019111904561230100_B1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"issue":"9976","key":"2019111904561230100_B2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2019111904561230100_B3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904561230100_B4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"9584","key":"2019111904561230100_B5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"20","key":"2019111904561230100_B6","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"suppl 4","key":"2019111904561230100_B7","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111904561230100_B8","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/724360","article-title":"Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells","volume-title":"Stem Cells Int","author":"Hamad","year":"2013"},{"issue":"1","key":"2019111904561230100_B9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2019111904561230100_B10","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"issue":"31","key":"2019111904561230100_B11","doi-asserted-by":"crossref","first-page":"27471","DOI":"10.1074\/jbc.M111.260547","article-title":"Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma","volume":"286","author":"Gandhi","year":"2011","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111904561230100_B12","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3945\/jn.111.141176","article-title":"Selenium levels affect the IL-4-induced expression of alternative activation markers in murine macrophages","volume":"141","author":"Nelson","year":"2011","journal-title":"J Nutr"},{"issue":"5","key":"2019111904561230100_B13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"14","key":"2019111904561230100_B14","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1158\/0008-5472.CAN-13-3694","article-title":"Selenium suppresses leukemia through the action of endogenous eicosanoids","volume":"74","author":"Gandhi","year":"2014","journal-title":"Cancer Res"},{"issue":"10","key":"2019111904561230100_B15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1940-6207.CAPR-15-0050","article-title":"Chemopreventive effects of dietary eicosapentaenoic acid supplementation in experimental myeloid leukemia","volume":"8","author":"Finch","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"issue":"10","key":"2019111904561230100_B16","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780.422k15_3780_3792","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"issue":"26","key":"2019111904561230100_B17","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1182\/blood-2010-11-317750","article-title":"\u039412-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice","volume":"118","author":"Hegde","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111904561230100_B18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"6","key":"2019111904561230100_B19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0887-2333(01)00085-6","article-title":"Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte\/macrophage (CFU-GM) assay","volume":"15","author":"Pessina","year":"2001","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"2019111904561230100_B20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nprot.2008.38","article-title":"Chromatin immunoprecipitation (ChIP) coupled to detection by quantitative real-time PCR to study transcription factor binding to DNA in Caenorhabditis elegans","volume":"3","author":"Mukhopadhyay","year":"2008","journal-title":"Nat Protoc"},{"issue":"7569","key":"2019111904561230100_B21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"3","key":"2019111904561230100_B22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2019111904561230100_B23","first-page":"65","article-title":"Mouse models as tools to understand and study BCR-ABL1 diseases","volume":"1","author":"Koschmieder","year":"2011","journal-title":"Am J Blood Res"},{"issue":"4","key":"2019111904561230100_B24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"issue":"6","key":"2019111904561230100_B25","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1074\/jbc.M109.053843","article-title":"Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3\/STAT5 activation","volume":"285","author":"Ross","year":"2010","journal-title":"J Biol Chem"},{"issue":"19","key":"2019111904561230100_B26","doi-asserted-by":"crossref","first-page":"16520","DOI":"10.1074\/jbc.M210572200","article-title":"Identification of Shp-2 as a Stat5A phosphatase","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111904561230100_B27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/eji.201041295","article-title":"DUSP4 deficiency enhances CD25 expression and CD4+ T-cell proliferation without impeding T-cell development","volume":"42","author":"Huang","year":"2012","journal-title":"Eur J Immunol"},{"issue":"10","key":"2019111904561230100_B28","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111904561230100_B29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/leu.2014.259","article-title":"CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia","volume":"29","author":"Korthuis","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2019111904561230100_B30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/scd.2013.0370","article-title":"Cited2 is required for the maintenance of glycolytic metabolism in adult hematopoietic stem cells","volume":"23","author":"Du","year":"2014","journal-title":"Stem Cells Dev"},{"issue":"4","key":"2019111904561230100_B31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1947601911409738","article-title":"The role of p53 in metabolic regulation","volume":"2","author":"Puzio-Kuter","year":"2011","journal-title":"Genes Cancer"},{"issue":"1","key":"2019111904561230100_B32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-inducible regulator of glycolysis and apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"issue":"4","key":"2019111904561230100_B33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1940-6207.CAPR-08-0055","article-title":"NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer","volume":"1","author":"Hughes","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"issue":"25","key":"2019111904561230100_B34","doi-asserted-by":"crossref","first-page":"17964","DOI":"10.1074\/jbc.M703075200","article-title":"The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages","volume":"282","author":"Vunta","year":"2007","journal-title":"J Biol Chem"},{"issue":"7503","key":"2019111904561230100_B35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"3","key":"2019111904561230100_B36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"issue":"16","key":"2019111904561230100_B37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","article-title":"Regulatory action on rosiglitazone by the U.S. Food and Drug Administration","volume":"363","author":"Woodcock","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/13\/1802\/1399613\/blood736405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/13\/1802\/1399613\/blood736405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T09:56:29Z","timestamp":1574157389000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/13\/1802\/35835\/Activation-of-PPAR%CE%B3-by-endogenous-prostaglandin-J2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,3,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-736405","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}